



SWISS BRIDGE AWARD 2018

500'000 CHF for Research on Immuno-oncology Biomarkers



October, 24th
Haus zum Rügen, Zürich

Two-stage evaluation process

With this year's call, the SWISS BRIDGE Foundation invited researchers under the age of 45 to close this knowledge gap. A total of 111 scientists from all over Europe applied for the SWISS BRIDGE Award 2018. The jury of respected experts used a two-stage evaluation process to finally select two projects.

Dr. Ping-Chih Ho with son,
Prof. Jakob Passweg (President),
Dr. Rodrigo Toledo,
Prof. Gordon McVie (Chairman of Scientific Jury),
Philipp Lücke (CEO)

Immunotherapies, such as checkpoint inhibitors – whose discoverers won this year's Nobel Prize for Physiology and Medicine – raise hope and are promising, because they can sometimes also cure patients with advanced-stage cancers. However, immunotherapies are also cause for frustration because they often fail, with only about 20% of the treated patients responding to these types of therapies. Medical science does not yet know in advance with whom these therapies will work.

Today, the two project leaders, **Dr. Ping-Chih Ho**, from the Ludwig Cancer Center, University of Lausanne, Switzerland, and **Dr. Rodrigo de Almeida Toledo**, from the Vall d'Hebron Institute of Oncology in Barcelona, Spain, **each receive CHF 250'000**, for the realization of their research projects.

Dr. Ping-Chih Ho's team is interested in the difference between tumors referred to as cold and hot tumors. While immunotherapies usually work well on hot tumors, they fail to work on cold tumors, because the cold tumor's surrounding environment apparently prevents immune cells from migrating into the tumor tissue and exerting their effect there. Recently, Ho and his team discovered a gene that is only active in hot tumors. In mice, the researchers even managed to activate the gene in cold tumors – and thus make the tumor environment accessible again to cancer-fighting immune cells. Now, this team of researchers would like to find out if the gene plays such a similar crucial role in humans – and shall perhaps develop a test to predict the answer to successful immunotherapy.

The research project of Dr. Rodrigo de Almeida Toledo and his team is about collecting samples from patients in Barcelona who have been treated with a variety of different immunotherapies. Genomic analysis – that is, the comparison of the entire genome in tumors of patients who respond well to therapy and that of genetic material in tumors which continue to grow despite the treatment – is intended to uncover differences that will not only inform the prediction of the response to immunotherapy that could be used in the future, but perhaps also provide a clue to possible new targets in the fight against tumors.

Donor's account: Credit Suisse, Zurich
IBAN: CH52 0483 5095 7385 1100 0

www.swissbridge.ch






NEWSLETTER

CHRISTMAS  2018**Evening Golf on 11 July 2018
at Golfpark Zürichsee**

It was a marvelous day of golf and a fantastic evening. Many thanks to everyone who participated and to all the sponsors for the outstanding support for this event. Thanks to the contributions that are fully available to SWISS BRIDGE, we can continue to guarantee our commitment to global cancer research in the years to come.

In 2019 as well, we will continue this event, and we are already looking forward to it. Save the date: 5 June 2019 at the Unterengstringen Golf Club. Further information and registration at: www.swissbridge.ch

**ADVENTSKONZERT**zur Förderung
junger Künstler aus der Schweiz**RISING STARS**Kirche St. Peter in Zürich
Donnerstag, 29. November 2018
18.00 Uhr

In Zusammenarbeit mit

RAHN KULTURFONDS
SWISS INTERNATIONAL CLUB
SWISS BRIDGE FOUNDATION**RISING STARS**

The SWISS INTERNATIONAL CLUB, a service club focusing on expats in Switzerland, and the SWISS BRIDGE Foundation have entered into a loose cooperation in the field of event organisation. The aim is to offer members, supporters and friends of the two organisations culturally and economically interesting activities to enable a wide-ranging network at all levels and across all areas.

At the same time, the administration costs can be reduced to a minimum. It is our great pleasure to invite you to the **RISING STARS** Advent concert to promote young artists from Switzerland on Thursday, 29 November 2018 at 6 p.m. at the Church of St. Peter in Zurich. Please register for the concert followed by an apéro riche at www.swissbridge.ch

The purpose of SWISS BRIDGE, founded in 1997, is to financially support high-quality Swiss and international research projects, which are expected to deliver new findings in the fight against cancer, through contributions from private donors and foundations. To date, a total of some 30 Mio Swiss Francs donations were received by SWISS BRIDGE for cancer research projects in Belgium, Brazil, England, France, Germany, Israel, Italy, Norway, Sweden, Spain and Switzerland.

Organization**Board of Foundation:**

Prof. Dr. Jakob Passweg, Chairman
Eleonore E. Droux
Thomas Hoepfli
Heinz Roth
Dr. Thomas Peter

Honorary President:

Prof. Dr. Giorgio Nosedà

Scientific Jury:

Prof. Dr. J. Gordon McVie, Chairman

Management:

Philipp Lücke, CEO

Administration:

SWISS BRIDGE, Postfach 1556, 8027 Zürich
Tel. +41 (0) 43 31 71 360
info@swissbridge.ch

For further information:

www.swissbridge.ch

Donor's account: Credit Suisse, Zurich
IBAN: CH52 0483 5095 7385 1100 0

If you know anyone, who may want to become a donor or a supporter and friend of the foundation SWISS BRIDGE, please contact us.

